Radiopharmaceutical for Targeted Treatment of Prostate Cancer to Enter Clinical Trials

Canadian centre of excellence partners with US-based Molecular Insight Pharmaceuticals to manufacture a new radiopharmaceutical for clinical trials that will evaluate the potential to deliver targeted radiotherapy directly to metastatic prostate cancer.

HAMILTON, ON, CANADA and CAMBRIDGE, MA, USA. (January 30, 2012)—A new targeted radiopharmaceutical, designed to deliver a therapeutic dose of radiation directly to metastatic prostate cancer, will be manufactured in Hamilton, Ontario to be used in clinical trials that will evaluate its efficacy and benefits for patients. The radiopharmaceutical, I-131-MIP-1466, will be manufactured by the Centre for Probe Development and Commercialization (CPDC, Hamilton, ON), for the developer of the compound, US-based Molecular Insight Pharmaceuticals (Molecular Insight, Cambridge, MA).